CHMP Recommends Brodalumab (Kyntheum) for Plaque Psoriasis
..The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a marketing authorization for brodalumab (Kyntheum, LEO Pharma, A/S) for the treatment of moderate to severe plaque..
Medscape. May 19, 2017 18:57 UTC